SCHEMBL23898541

SCHEMBL23898541

N#Cc1c(C2CCC2)n(-c2ccccc2)c2ccc(O)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.44
GFER P55789 1/20 0.44
HTT P42858 4/20 0.41
HPGD P15428 3/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 5/20 0.39
MAPT P10636 4/20 0.39
ALOX15 P16050 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
PKM P14618 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23898529 0.90 GAA (0.42) GAAGFERHTTHPGDLMNA
SCHEMBL23898361 0.88 KDM4E (0.36) GAAGFERHTTLMNASMN1; SMN2
SCHEMBL23898531 0.83 KDM4E (0.37) GAAGFERHTTLMNASMN1; SMN2
SCHEMBL23898530 0.83 GAA (0.38) GAAGFERHTTHPGDLMNA
SCHEMBL23898532 0.78 KCNH2 (0.40) GAAKDM4E
SCHEMBL30176384 0.78 SCN9A (0.36) GAAGFERLMNAKDM4EALDH1A1
SCHEMBL23887039 0.78 SCN9A (0.36) GAAGFERLMNAKDM4EALDH1A1
SCHEMBL23898537 0.75 KDM4E (0.35) GAAGFERHTTHPGDLMNA
SCHEMBL23898538 0.72 ALDH1A1 (0.34) GAAHTTKDM4EMEN1KMT2A
SCHEMBL14627882 0.70 GAA (0.61) GAAGFERHTTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339915-A1 MODULATORS OF ALPHA-1 ANTITRYPSIN VERTEX PHARMACEUTICALS INCORPORATED 2023-10-26 US disclosed
US-20230339915-A1 MODULATORS OF ALPHA-1 ANTITRYPSIN VERTEX PHARMACEUTICALS INCORPORATED 2023-10-26 US disclosed
WO-2021203007-A1 SUBSTITUTED 5-HYDROXYINDOLE COMPOUNDS AS MODULATORS OF ALPHA-1 ANTITRYPSIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339915-A1 MODULATORS OF ALPHA-1 ANTITRYPSIN SERPINA2, SERPINA3, SERPINB1 GAA 139/4885GFER 2801/4885HTT 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.